Healthcare Services

A significant industry trend in the Idiopathic Pulmonary Fibrosis Market includes the Groundbreaking Anti-Fibrotic Small-Molecule Inhibitor Paving The Way In Idiopathic Pulmonary Fibrosis Treatment

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Idiopathic Pulmonary Fibrosis Market In 2026 And What Value Is Projected For 2030?

The idiopathic pulmonary fibrosis market has demonstrated robust growth over recent years. Projections indicate it will expand from $4.37 billion in 2025 to $4.66 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.7%. This historical market expansion can be credited to several factors, including the limited availability of treatment options for fibrotic lung diseases, a rising prevalence of the aging population, improved clinical recognition of IPF, the approval of nintedanib and pirfenidone, and an increase in hospital-based management for chronic lung disorders.

The idiopathic pulmonary fibrosis market is projected for significant expansion in the coming years. This market is anticipated to reach $6.16 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. Factors driving this growth during the forecast period include increasing investment in pulmonary fibrosis research, the emergence of next-generation antifibrotic medications, wider application of real-world evidence for treatment choices, the expansion of online and specialized pharmacy routes, and heightened public awareness of rare respiratory conditions. Key trends anticipated over this period involve greater uptake of antifibrotic treatments, a stronger emphasis on prompt and precise diagnosis, an increase in combination drug regimens, the broadening of home-based and long-term disease management solutions, and enhanced involvement in clinical trials for new therapeutic options.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Idiopathic Pulmonary Fibrosis Market?

The idiopathic pulmonary fibrosis market is anticipated to experience growth due to an expanding geriatric population. This demographic specifically denotes the elderly or senior citizens within a particular society. Aging is linked to alterations in lung structure and function, which makes older individuals more vulnerable to respiratory illnesses like IPF. This heightened susceptibility associated with age contributes to the overall need for IPF treatments. For instance, in January 2024, the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, signifying a 47% rise. As a consequence, this age group’s share of the total U.S. population will grow from 17% to 23% over this timeframe. Thus, the increasing geriatric population is a key driver for the expansion of the idiopathic pulmonary fibrosis market.

What Are The Key Segments Of The Idiopathic Pulmonary Fibrosis Market?

The idiopathic pulmonary fibrosis market covered in this report is segmented –

1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types

2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers

5) By End Users: Hospitals And Clinics, Other End Users

Subsegments:

1) By Nintedanib: Indications, Dosage Forms, Administration Routes

2) By Pirfenidone: Indications, Dosage Forms, Administration Routes

3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies

What Trends Are Projected To Affect The Idiopathic Pulmonary Fibrosis Market?

Major companies in the idiopathic pulmonary fibrosis (IPF) market are prioritizing novel products, such as anti-fibrotic small-molecule inhibitors, to maintain their market presence. These inhibitors are pharmaceutical compounds designed to target and suppress fibrotic processes in the body. For example, in June 2023, Insilico Medicine, a US-based clinical-stage biotechnology company utilizing generative artificial intelligence (AI), announced the commencement of Phase II clinical trials for INS018_055. This marks the world’s first anti-fibrotic small molecule inhibitor created through generative AI, with the initial dose administered to patients in a randomized, double-blind, placebo-controlled study. The trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of a 12-week oral dosage of INS018_055 in individuals with idiopathic pulmonary fibrosis (IPF). This AI-driven approach in drug discovery represents a significant potential advancement in the treatment of idiopathic pulmonary fibrosis (IPF) diseases.

Who Are The Leading Companies Operating In The Idiopathic Pulmonary Fibrosis Market?

Major companies operating in the idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

Read the full idiopathic pulmonary fibrosis market report here:

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

What Are The Leading Geographic Regions In The Idiopathic Pulmonary Fibrosis Market?

North America was the largest region in the idiopathic pulmonary fibrosis market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Idiopathic Pulmonary Fibrosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12579&type=smp

Browse Through More Reports Similar to the Global Idiopathic Pulmonary Fibrosis Market 2026, By The Business Research Company

Non Cystic Fibrosis Bronchiectasis Global Market Report

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

Interstitial Lung Disease Global Market Report

https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

Cystic Fibrosis Cf Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795